Literature DB >> 25084322

Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues.

Chunyi Wang1, Jinghe Mao2, Samantha Redfield3, Yinyuan Mo4, Janice M Lage5, Xinchun Zhou6.   

Abstract

AIMS: Five sphingosine-1-phosphate receptors (S1PR): S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 (S1PR1-5) have been shown to be involved in the proliferation and progression of various cancers. However, none of the S1PRs have been systemically investigated. In this study, we performed immunohistochemistry (IHC) for S1PR1-S1PR5 on different tissues, in order to simultaneously determine the systemic distribution, subcellular localization and expression level of all five S1PRs.
METHODS: We constructed tissue microarrays (TMAs) from 384 formalin-fixed paraffin-embedded (FFPE) blocks containing 183 benign and 201 malignant tissues from 34 human organs/systems. Then we performed IHC for all five S1PRs simultaneously on these TMA slides. The distribution, subcellular localization and expression of each S1PR were determined for each tissue. The data in benign and malignant tissues from the same organ/tissue were then compared using the Student's t-test. In order to reconfirm the subcellular localization of each S1PR as determined by IHC, immunocytochemistry (ICC) was performed on several malignant cell lines.
RESULTS: We found that all five S1PRs are widely distributed in multiple human organs/systems. All S1PRs are expressed in both the cytoplasm and nucleus, except S1PR3, whose IHC signals are only seen in the nucleus. Interestingly, the S1PRs are rarely expressed on cellular membranes. Each S1PR is unique in its organ distribution, subcellular localization and expression level in benign and malignant tissues. Among the five S1PRs, S1PR5 has the highest expression level (in either the nucleus or cytoplasm), with S1PR1, 3, 2 and 4 following in descending order. Strong nuclear expression was seen for S1PR1, S1PR3 and S1PR5, whereas S1PR2 and S1PR4 show only weak staining. Four organs/tissues (adrenal gland, liver, brain and colon) show significant differences in IHC scores for the multiple S1PRs (nuclear and/or cytoplasmic), nine (stomach, lymphoid tissues, lung, ovary, cervix, pancreas, skin, soft tissues and uterus) show differences for only one S1PR (cytoplasmic or nuclear), and twenty three organs/tissues show no significant difference in IHC scores for any S1PR (cytoplasmic or nuclear) between benign and malignant changes.
CONCLUSION: This is the first study to evaluate the expression level of all S1PRs in benign and malignant tissues from multiple human organs. This study provides data regarding the systemic distribution, subcellular localization and differences in expression of all five S1PRs in benign and malignant changes for each organ/tissue.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenal gland; Cancer; Colon; Immunohistochemistry (IHC); Liver; Lung; Neural system; Ovary; Sphingosine-1-phosphate (S1P) receptors (S1PRs); Stomach

Mesh:

Substances:

Year:  2014        PMID: 25084322      PMCID: PMC4177454          DOI: 10.1016/j.yexmp.2014.07.013

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  40 in total

1.  Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.

Authors:  Robert Schmouder; Sam Hariry; Olivier J David
Journal:  Eur J Clin Pharmacol       Date:  2011-11-10       Impact factor: 2.953

2.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

Review 3.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

4.  Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate.

Authors:  G Zhang; J J Contos; J A Weiner; N Fukushima; J Chun
Journal:  Gene       Date:  1999-02-04       Impact factor: 3.688

5.  The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.

Authors:  Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler
Journal:  Exp Mol Pathol       Date:  2011-11-11       Impact factor: 3.362

Review 6.  Sphingosine 1-phosphate: a prototype of a new class of second messengers.

Authors:  S Spiegel
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

7.  Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.

Authors:  James Van Brocklyn; Catherine Letterle; Pamela Snyder; Thomas Prior
Journal:  Cancer Lett       Date:  2002-07-26       Impact factor: 8.679

8.  EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue.

Authors:  M H Gräler; G Bernhardt; M Lipp
Journal:  Genomics       Date:  1998-10-15       Impact factor: 5.736

9.  ETS-1-mediated transcriptional up-regulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis.

Authors:  Wenliang Zhang; Jiawei Zhao; Jen-Fu Lee; Allison Gartung; Hiba Jawadi; Wanyu Louis Lambiv; Kenneth V Honn; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

10.  Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer.

Authors:  J Ohotski; J S Long; C Orange; B Elsberger; E Mallon; J Doughty; S Pyne; N J Pyne; J Edwards
Journal:  Br J Cancer       Date:  2012-03-29       Impact factor: 7.640

View more
  29 in total

Review 1.  Advancements in understanding the role of lysophospholipids and their receptors in lung disorders including bronchopulmonary dysplasia.

Authors:  Tara Sudhadevi; Alison W Ha; David L Ebenezer; Panfeng Fu; Vijay Putherickal; Viswanathan Natarajan; Anantha Harijith
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-10       Impact factor: 4.698

2.  Syntheses and in vitro biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates.

Authors:  Zonghua Luo; Junbin Han; Hui Liu; Adam J Rosenberg; Delphine L Chen; Robert J Gropler; Joel S Perlmutter; Zhude Tu
Journal:  Org Biomol Chem       Date:  2018-12-05       Impact factor: 3.876

Review 3.  Nuclear Lipids in the Nervous System: What they do in Health and Disease.

Authors:  Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Neurochem Res       Date:  2016-10-20       Impact factor: 3.996

4.  Methylation-driven genes and their prognostic value in cervical squamous cell carcinoma.

Authors:  Jinhui Liu; Sipei Nie; Siyue Li; Huangyang Meng; Rui Sun; Jing Yang; Wenjun Cheng
Journal:  Ann Transl Med       Date:  2020-07

Review 5.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 6.  Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair.

Authors:  Ziad Sartawi; Ernestina Schipani; Katie B Ryan; Christian Waeber
Journal:  Pharmacol Res       Date:  2017-09-22       Impact factor: 7.658

Review 7.  Nuclear lipid mediators: Role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression.

Authors:  Panfeng Fu; David L Ebenezer; Alison W Ha; Vidyani Suryadevara; Anantha Harijith; Viswanathan Natarajan
Journal:  J Cell Biochem       Date:  2018-05-08       Impact factor: 4.429

8.  Divergence of Intracellular Trafficking of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Receptor 3 in MCF-7 Breast Cancer Cells and MCF-7-Derived Stem Cell-Enriched Mammospheres.

Authors:  Olga A Sukocheva; Dong Gui Hu; Robyn Meech; Anupam Bishayee
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 9.  The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.

Authors:  Samuel F Hunter; James D Bowen; Anthony T Reder
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

10.  Extracellular Matrix Rigidity-dependent Sphingosine-1-phosphate Secretion Regulates Metastatic Cancer Cell Invasion and Adhesion.

Authors:  Panseon Ko; Daehwan Kim; Eunae You; Jangho Jung; Somi Oh; Jaehyun Kim; Kwang-Ho Lee; Sangmyung Rhee
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.